Skip to content
10-Q

Quarterly Report

Verrica Pharmaceuticals Inc. VRCA

0001660334-26-000014

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 17.18M sh
Shares Diluted Q1 2026 · Mar 31, 2026 21.31M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 9.48M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.16M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.68M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $20.6M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $30.15M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $29.6M
Stockholders Equity Q1 2026 · Mar 31, 2026 $16.06M
Stockholders Equity Q1 2026 · Dec 31, 2025 $24.74M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$18.58M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$9.86M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.22M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $22.73M
Total Liabilities Q1 2026 · Dec 31, 2025 $22.39M
Current Assets Q1 2026 · Mar 31, 2026 $34.13M
Current Assets Q1 2026 · Dec 31, 2025 $42.54M
Total Assets Q1 2026 · Mar 31, 2026 $38.79M
Total Assets Q1 2026 · Dec 31, 2025 $47.13M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.45
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$1.03
Eps Basic Q1 2026 · Mar 31, 2026 −$0.45
Eps Basic restated Q1 2026 · Mar 31, 2025 −$1.03
Sga Expense Q1 2026 · Mar 31, 2026 $9.99M
Sga Expense Q1 2026 · Mar 31, 2025 $8.85M
Rd Expense Q1 2026 · Mar 31, 2026 $3.86M
Rd Expense Q1 2026 · Mar 31, 2025 $2.28M
Net Income Q1 2026 · Mar 31, 2026 −$9.68M
Net Income Q1 2026 · Mar 31, 2025 −$9.74M
Operating Income Q1 2026 · Mar 31, 2026 −$9.72M
Operating Income Q1 2026 · Mar 31, 2025 −$8.13M
Stock Issued Q1 2026 · Nov 30, 2025 6.5M sh